In a recent study, more than 90% of people who had their stomach removed to prevent cancer have at least one chronic problem 2 years after their surgery. For some, the problems are life altering.
The Food and Drug Administration (FDA) approved toripalimab (Loqtorzi) for nasopharyngeal cancer that has come back or spread after treatment. The results from a large clinical trial showed that, when added to chemotherapy, the drug increased how long people with this cancer lived.
Under a new FDA approval, enzalutamide (Xtandi) can now be used alone, or with leuprolide, to treat some people with prostate cancer. This approval adds to the number of treatment options for prostate cancer that has greatly increased over the last decade.
Religion and spirituality in cancer care are very personal matters that can affect your treatment decisions and the ability to cope. Learn how your health care team can support your spiritual and religious well-being and how this can lead to improved health and quality of life.
